NervGen (NGEN) prices $60M public offering at $2.50 per share

NervGen Pharma (NGEN) has announced the pricing of its public offering at $2.50 per share, aiming to raise approximately $60 million. This financing will support the company's ongoing clinical development and operational expenses. The share price reflects a specific valuation and may influence investor sentiment and future stock performance. This capital infusion could impact ongoing projects and potential market strategies moving forward.